The Therapeutic Goods Administration (TGA) has this week approved the registration of a range of medically approved vaporisers in Australia.
The approval of the Storz & Bickel GmbH & Co. KG medical standard vaporisers has been welcomed by Spectrum Therapeutics Australia (Spectrum), the medical division of Canopy Growth Corporation Australia (Canopy), owners of the Storz & Bickel brand.
Storz & Bickel is among the world’s leading companies in the field of medically approved vaporiser design and manufacturing. The company spent many years developing its Canada based automated, ISO 134851 certified factory and sells a range of vaporisers and vaping products including the Volcano Medic and Mighty Medic.
Canopy’s Asia-Pacific Managing Director, Ben Quirin said, “Medicinal cannabis is not a one-size-fits-all approach, so having a registered device available for patients is crucial to ensuring a range of products is available locally that meet the diverse needs of patients, and can be administered safely with the support of their medical professional.”
Canopy launched its Spectrum Therapeutic Asia-Pacific Headquarters last year and to date has been importing its full suite of products from the facility in Canada, all of which have been tested to comply with TG093 standards. Though located in Victoria, Canada, the factory has been retrofitted and licensed to meet Australian regulatory standards.
Speaking of Canopy’s future plans, Mr Quirin said, “Patient numbers are growing in Australia, as seen in the SAS approval numbers. While we currently import our products from Canada, our first priority has always been to deliver locally produced medicinal cannabis products for patients.
Mr Quirin confirmed the company have secured the permits required to start factory construction in Australia, and expect completion by Q1 2020.
“Our completed facility will produce approximately 15,500kg of dry flower per year, which we will use to develop standardised and GMP-certified dried flower, oil and Softgel capsules,” he said.